WallStreetZenWallStreetZen

NASDAQ: CRIS
Curis Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CRIS

Based on 1 analyst offering 12 month price targets for Curis Inc

Min Forecast
$43.00+4,416.81%
Avg Forecast
$43.00+4,416.81%
Max Forecast
$43.00+4,416.81%

Should I buy or sell CRIS stock?

Based on 1 analyst offering ratings for Curis Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CRIS's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates CRIS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their CRIS stock forecasts and price targets.

CRIS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-17

1 of 1

Forecast return on equity

Is CRIS forecast to generate an efficient return?

Company
-354.18%
Industry
20.49%
Market
168.97%
CRIS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRIS forecast to generate an efficient return on assets?

Company
-87.66%
Industry
23.56%
CRIS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRIS earnings per share forecast

What is CRIS's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$24.55
Avg 2 year Forecast
-$6.13
Avg 3 year Forecast
-$7.04

CRIS revenue forecast

What is CRIS's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$2.6M-40.89%
Avg 2 year Forecast
$9.9M+130.53%
Avg 3 year Forecast
$43.3M+903.69%
CRIS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CRIS revenue growth forecast

How is CRIS forecast to perform vs Biotechnology companies and vs the US market?

Company
107.02%
Industry
31.35%
Market
13.89%
CRIS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CRIS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CRIS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRIS$0.95$43.00+4,416.81%Buy
SPRC$5.01N/AN/A
CMND$0.85N/AN/A
OGEN$0.49N/AN/A
SLXN$0.32N/AN/A
View Top Biotech Stocks

Curis Stock Forecast FAQ

Is Curis Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CRIS) stock is to Buy CRIS stock.

Out of 1 analyst, 0 (0%) are recommending CRIS as a Strong Buy, 1 (100%) are recommending CRIS as a Buy, 0 (0%) are recommending CRIS as a Hold, 0 (0%) are recommending CRIS as a Sell, and 0 (0%) are recommending CRIS as a Strong Sell.

If you're new to stock investing, here's how to buy Curis stock.

What is CRIS's earnings growth forecast for 2026-2028?

(NASDAQ: CRIS) Curis's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.92%.

Curis's earnings in 2026 is -$21,153,000.On average, 6 Wall Street analysts forecast CRIS's earnings for 2026 to be -$51,303,657, with the lowest CRIS earnings forecast at -$66,527,987, and the highest CRIS earnings forecast at -$34,345,190. On average, 6 Wall Street analysts forecast CRIS's earnings for 2027 to be -$12,819,696, with the lowest CRIS earnings forecast at -$16,365,721, and the highest CRIS earnings forecast at -$6,956,821.

In 2028, CRIS is forecast to generate -$14,709,962 in earnings, with the lowest earnings forecast at -$19,192,341 and the highest earnings forecast at -$9,721,993.

What is CRIS's revenue growth forecast for 2026-2028?

(NASDAQ: CRIS) Curis's forecast annual revenue growth rate of 107.02% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.35%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.89%.

Curis's revenue in 2026 is $4,314,000.On average, 6 Wall Street analysts forecast CRIS's revenue for 2026 to be $5,329,696, with the lowest CRIS revenue forecast at $0, and the highest CRIS revenue forecast at $21,945,809. On average, 6 Wall Street analysts forecast CRIS's revenue for 2027 to be $20,785,816, with the lowest CRIS revenue forecast at $0, and the highest CRIS revenue forecast at $85,588,653.

In 2028, CRIS is forecast to generate $90,498,244 in revenue, with the lowest revenue forecast at $12,084,825 and the highest revenue forecast at $173,371,887.

What is CRIS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CRIS) forecast ROA is -87.66%, which is lower than the forecast US Biotechnology industry average of 23.56%.

What is CRIS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CRIS price target, the average CRIS price target is $43.00, with the highest CRIS stock price forecast at $43.00 and the lowest CRIS stock price forecast at $43.00.

The Wall Street analyst predicted that Curis's share price could reach $43.00 by Aug 17, 2027. The average Curis stock price prediction forecasts a potential upside of 4,416.81% from the current CRIS share price of $0.95.

What is CRIS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CRIS) Curis's current Earnings Per Share (EPS) is -$6.62. On average, analysts forecast that CRIS's EPS will be -$24.55 for 2026, with the lowest EPS forecast at -$31.83, and the highest EPS forecast at -$16.43. On average, analysts forecast that CRIS's EPS will be -$6.13 for 2027, with the lowest EPS forecast at -$7.83, and the highest EPS forecast at -$3.33. In 2028, CRIS's EPS is forecast to hit -$7.04 (min: -$9.18, max: -$4.65).

What is CRIS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CRIS) forecast ROE is -354.18%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.